ANIK

17.04

1.22% -0.21

Handel nachbörslich: 17.00 -0.04 -0.23%

Anika Therapeutics Inc (ANIK)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$17.25

Offen:

$17.19

24-Stunden-Volumen:

110.13K

Relative Volume:

1.45

Marktkapitalisierung:

$249.56M

Einnahmen:

$166.88M

Nettoeinkommen (Verlust:

$-74.18M

KGV:

-11.14

EPS:

-1.53

Netto-Cashflow:

$1.14M

1W Leistung:

-0.18%

1M Leistung:

-32.00%

6M Leistung:

-32.91%

1J Leistung:

-18.86%

1-Tages-Spanne:

$16.80

$17.35

1-Wochen-Bereich:

$16.41

$17.35

52-Wochen-Spanne:

$16.00

$29.11

Anika Therapeutics Inc Stock (ANIK) Company Profile

Firmenname

Anika Therapeutics Inc

Sektor

Healthcare (1196)

Branche

Drug Manufacturers - Specialty & Generic (87)

Telefon

(781) 457-9000

Adresse

32 WIGGINS AVENUE, BEDFORD, MA

Mitarbeiter

357

Twitter

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

ANIK's Discussions on Twitter

Vergleichen Sie ANIK mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ANIK	17.04	249.56M	166.88M	-74.18M	1.14M	-1.53
ZTS	176.42	79.51B	9.15B	2.43B	2.31B	4.92
TAK	13.53	42.89B	30.27B	1.93B	3.45B	0.444
HLN	9.43	42.57B	14.26B	1.55B	0	0.3327
TEVA	16.49	18.51B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.00	15.37B	15.24B	-646.50M	1.88B	1.53

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-08-14	Hochstufung	Barrington Research	Mkt Perform → Outperform
2023-03-07	Herabstufung	Barrington Research	Outperform → Mkt Perform
2022-11-09	Hochstufung	Barrington Research	Mkt Perform → Outperform
2022-10-14	Fortgesetzt	Stephens	Equal-Weight
2022-03-09	Herabstufung	Barrington Research	Outperform → Mkt Perform
2022-03-09	Herabstufung	Stephens	Overweight → Equal-Weight
2021-11-16	Eingeleitet	Stephens	Overweight
2021-07-16	Eingeleitet	UBS	Neutral
2020-12-16	Hochstufung	Barrington Research	Mkt Perform → Outperform
2020-05-08	Herabstufung	Barrington Research	Outperform → Mkt Perform
2020-01-21	Hochstufung	Sidoti	Neutral → Buy
2020-01-10	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2019-11-05	Eingeleitet	BWS Financial	Sell
2019-09-24	Bestätigt	Barrington Research	Outperform
2019-09-23	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2019-07-25	Hochstufung	First Analysis Sec	Neutral → Strong Buy
2019-02-22	Herabstufung	First Analysis Sec	Outperform → Neutral
2019-02-22	Herabstufung	Sidoti	Buy → Neutral
2018-07-27	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-06-20	Herabstufung	Barrington Research	Outperform → Mkt Perform
2018-06-20	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2018-05-04	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-02-23	Herabstufung	Barrington Research	Outperform → Mkt Perform
2018-01-24	Hochstufung	First Analysis Sec	Equal-Weight → Overweight
2017-10-27	Bestätigt	Barrington Research	Outperform
2016-05-09	Hochstufung	Singular Research	BUY - Long-Term → Buy
2016-04-27	Herabstufung	Northland Capital	Outperform → Market Perform
2016-02-26	Bestätigt	Barrington Research	Outperform

Alle ansehen

Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten

Nov 08, 2024

Orthobiologics Market Size, Growth, Opportunities 2024-2032 | - openPR

Nov 08, 2024

Nov 06, 2024

Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts - TipRanks

Nov 06, 2024

Nov 05, 2024

Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA - MarketBeat

Nov 05, 2024

Anika Therapeutics Announces Third Quarter Financial ResultsOn October 31, 2024, Anika Therapeutics, Inc. released a press statement unveiling its financial outcomes for the third quarter concluding on September 30, 2024. As per the report - Defense World

Nov 05, 2024

Viscosupplementation Market Report Analysis, Growth - openPR

Nov 05, 2024

Nov 04, 2024

Anika Therapeutics (NASDAQ:ANIK) Downgraded to Hold Rating by StockNews.com - MarketBeat

Nov 04, 2024

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 04, 2024

Barrington Research Cuts Anika Therapeutics (NASDAQ:ANIK) Price Target to $25.00 - Defense World

Nov 04, 2024

Nov 03, 2024

Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring By Investing.com - Investing.com South Africa

Nov 03, 2024

Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring - Investing.com

Nov 03, 2024

Nov 02, 2024

Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 02, 2024

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024

Nov 01, 2024

Anika Therapeutics (NASDAQ:ANIK) Given New $25.00 Price Target at Barrington Research - MarketBeat

Nov 01, 2024

Anika Therapeutics (NASDAQ:ANIK shareholders incur further losses as stock declines 30% this week, taking five-year losses to 72% - Simply Wall St

Nov 01, 2024

Anika: Q3 Earnings Snapshot - New Haven Register

Nov 01, 2024